Voyager Therapeutics announces data from SAD trial of VY7523

Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational anti-tau antibody developed to selectively inhibit the spread of pathological tau in Alzheimer’s disease, AD. In the SAD trial, data on VY7523 delivered intravenously demonstrated safety, tolerability, and dose-proportional pharmacokinetics. Voyager has initiated a multiple ascending dose trial of VY7523 in patients with early AD, which is expected to generate initial tau positron emission tomography imaging data in the second half of 2026. “We continue to view tau as the most exciting target in Alzheimer’s disease, which is why we are advancing two tau-targeting approaches, our anti-tau antibody and our tau silencing gene therapy,” said Toby Ferguson, M.D., Ph.D., Chief Medical Officer of Voyager Therapeutics. “For the antibody approach, we believe VY7523 could be best-in-class due to the emerging PK data and previous preclinical data showing 70% reduction in tau spread, as well as its specificity for pathological tau and for a unique C-terminal epitope. We look forward to third-party data later this year and early next year, which could continue to build excitement around tau ahead of our VY7523 tau PET data.”